Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a class of medications that help improve the function of the atypical protein causing cystic fibrosis. According to the ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

The dire circumstances facing cystic fibrosis patients in Cuba have come to light through a heartfelt letter sent to our news ...

An additional 94 non-F508del CFTR mutations and a boxed warning on liver injury and liver failure were included in the updated prescribing information. 1507_1515del9, 2183A→G, A1067P ...

Because cystic fibrosis affects multiple organ systems, including the lungs and digestive system, people with the condition often need care from a team of healthcare professionals. Cystic fibrosis ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and ...